ArticleCancer causes & control : CCC2026
Urinary metabolites of 1,3-butadiene, benzene and toluene and colorectal cancer incidence: a clinical case-control study.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWorkplace exposure to volatile organic compounds (VOCs) has been shown to have a positive association with colorectal cancer (CRC) mortality. Benzene, 1,3-butadiene, and toluene are known carcinogens for other cancers. However, the effect of non-occupational VOC exposures on CRC is unknown.
methodsA clinical case-control study was performed. CRC cases were enrolled; controls were those patients seen for routine screening. Participants completed a detailed questionnaire and provided urine samples. Urinary VOC metabolites were measured for metabolites of: benzene metabolites (MU, PPMA, PMA), 1,3-butadiene (DHBMA, MHBMA1, MHBMA3), and toluene (BMA) for 43 CRC Cases and 104 controls. Concentrations were creatinine normalized and dichotomized as high or low. Logistic regression was used to estimate Odds Ratios (ORs) of CRC with 95% Confidence Intervals (CI) comparing high to low exposure adjusted for confounding factors.
resultsHigh levels of the MHBMA3 had 2.62 (95% CI 1.09, 6.31) times higher odds of having CRC compared to those with low levels after confounding adjustment. The adjusted ORs of CRC were elevated for Benzene PPMA (OR = 2.12 95%CI 0.92, 4.88). The metabolites BMA, MU, PMA, and other metabolites of 1,3-butadiene were not associated with CRC.
conclusionsMHBMA3 (a metabolite of 1,3-butadiene) was associated with a higher incidence of CRC independent of smoking and other CRC risk factors. Non-smoking sources of 1,3-butadiene, such as environmental sources, may contribute to increasing CRC incidence. Additional epidemiologic studies are needed to confirm this observation. Further laboratory studies are required to identify potential biologic mechanisms specific to MHBMA3 and colorectal carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.